Please login to the form below

Not currently logged in
Email:
Password:

Creabilis names Catherine Moukheibir as chairman of the board

She has previously held roles at Ablynx, Movetis and Innate Pharma

edit-Creabilis-Catherine-MoukheibirDermatology firm Creabilis has appointed Catherine Moukheibir as chairman of its board of directors.

Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.

Commenting on her appointment, Moukheibir said: “I am delighted to have been appointed to lead the Creabilis Board at this important time in the Company's development. 

“The potential of CT327 in the treatment of pruritic conditions is a significant opportunity and the data reported so far demonstrates the power of Creabilis' pipeline and its unique low systemic exposure platform technology.”

Moukheibir has a wide range of experience in aligning corporate goals with financial strategy. 

After an initial career in strategy consulting and investment banking, she held a number of senior management role at European biotech firms including CFO at Movetis, non-executive board member at Ablynx and member of the management board at Innate Pharma.

Last November, Moukheiber was also named as an observer to Zealand's board of directors.

2nd June 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics